PRESS RELEASE published on 11/10/2023 at 06:30, 2 years ago Formycon hosts conference call on nine-month figures 2023 and presents at further investor conferences
PRESS RELEASE published on 10/10/2023 at 07:30, 2 years 1 month ago Formycon Ranibizumab Biosimilar FYB201/CIMERLI®1 achieved 25% market share2 in the United States
PRESS RELEASE published on 09/29/2023 at 07:30, 2 years 2 months ago Formycon and Fresenius Kabi announce European Medicines Agency Submission Acceptance of the Marketing Authorization Application for FYB202, an Ustekinumab Biosimilar Candidate
PRESS RELEASE published on 08/30/2023 at 07:30, 2 years 3 months ago Formycon reports successful first half of 2023
PRESS RELEASE published on 08/29/2023 at 07:30, 2 years 3 months ago Formycon announces File Acceptance for FYB203, a biosimilar candidate to Eylea®1 (aflibercept), by the U.S. Food and Drug Administration (FDA)
PRESS RELEASE published on 08/23/2023 at 07:30, 2 years 3 months ago Formycon hosts conference call on financial and earnings position for H1 2023
PRESS RELEASE published on 08/21/2023 at 13:42, 2 years 3 months ago Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
PRESS RELEASE published on 08/07/2023 at 08:00, 2 years 3 months ago Formycon and Fresenius Kabi secure U.S. License Date for proposed Ustekinumab Biosimilar
PRESS RELEASE published on 07/26/2023 at 07:30, 2 years 4 months ago Formycon reports on the regular Annual General Meeting
PRESS RELEASE published on 06/29/2023 at 07:30, 2 years 5 months ago Formycon announces submission of the biologics license application (BLA) for FYB203, an aflibercept biosimilar candidate to the U.S. Food and Drug Administration (FDA)
Published on 12/05/2025 at 02:35, 8 hours 1 minute ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 9 hours 36 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 11 hours 31 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 11 hours 36 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 10:15, 21 minutes ago Wuxi’s Liangxi District: Where 3,000 Years of Jiangnan Culture Thrives
Published on 12/05/2025 at 09:40, 56 minutes ago Chery Partners with 2025 Asian Youth Para Games, Taking Center Stage in Global Sports with Passion and Aspiration
Published on 12/05/2025 at 09:30, 1 hour 6 minutes ago REPLOID Group AG: Exhibitor at the BIOGAS Convention & Trade Fair in Nuremberg, Germany
Published on 12/05/2025 at 09:05, 1 hour 31 minutes ago Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis
Published on 12/05/2025 at 09:00, 1 hour 36 minutes ago Original-Research: DEMIRE AG (von NuWays AG): BUY
Published on 12/05/2025 at 08:45, 1 hour 51 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 16 hours 36 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 16 hours 51 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 16 hours 52 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 3 hours ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
